Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celldex Therapeutics Inc CLDX

Healthcare Biotechnology
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody... see more

Recent & Breaking News (NDAQ:CLDX)

Celldex to Participate in Upcoming Investor Conferences

GlobeNewswire November 11, 2021

Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2021

Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021

GlobeNewswire September 29, 2021

Celldex to Present at the 2021 Cantor Virtual Global Healthcare Conference

GlobeNewswire September 24, 2021

Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress

GlobeNewswire September 23, 2021

Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study

GlobeNewswire September 13, 2021

Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire August 5, 2021

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire July 16, 2021

Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock

GlobeNewswire July 13, 2021

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire July 12, 2021

Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021

GlobeNewswire July 9, 2021

Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting

GlobeNewswire June 4, 2021

Celldex Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021

GlobeNewswire June 1, 2021

Celldex to Present at the Jefferies 2021 Virtual Healthcare Conference

GlobeNewswire May 26, 2021

Celldex Reports First Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire May 6, 2021

Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021

GlobeNewswire April 12, 2021

Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results

GlobeNewswire March 29, 2021

Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria

GlobeNewswire March 29, 2021

Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 5, 2021

Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN)

GlobeNewswire February 22, 2021